The alkynylphosphonate analogue of calcitriol EM1 has potent anti-metastatic effects in breast cancer

FERRONATO, M.J.; OBIOL, D. J.; FERMENTO, M.E.; GANDINI, N.A.; ALONSO, E.N.; SALOMÓN, D.G.; VITALE, C.; MASCARÓ, E.; FALL,Y.; RAIMONDI, A.R.; CURINO, A.C.; FACCHINETTI, M.M.

JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

PERGAMON-ELSEVIER SCIENCE LTD

Lugar: Amsterdam; Año: 2015 vol. 154 p. 285 - 293

0960-0760

The active form of vitamin D3, calcitriol, plays a major role in maintaining calcium/phosphate homeostasis. In addition, it is a potent antiproliferative and pro-differentiating agent. However, when effective antitumor doses of calcitriol are employed, hypercalcemic effects are observed, thus precluding its therapeutic application. To overcome this problem, structural analogs have been designed with the aim at retaining or even increasing the antitumor effects while decreasing its calcemic activity. This report shows the biological evaluation of an alkynylphosphonate vitamin D less-calcemic analogue in a murine model of breast cancer. We demonstrate that this compound has potent anti-metastatic effects through its action over cellular migration and invasion likely mediated through the up-regulation of E- cadherin expression. Based on the current in vitro and in vivo results, EM1 is a promising candidate as a therapeutic agent in breast cancer.